A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

Exclusion Criteria

• •Co-existing Condition:
• •Patients with ocular conditions requiring immediate surgical correction are excluded.
• •Concurrent Medication:
• •Excluded during first 4 weeks of ganciclovir treatment:
• •Zidovudine (AZT).
• •Excluded:
• •Other investigational drugs and antimetabolites, alkylating agents, nucleoside analogs (topical ophthalmics are permitted), acyclovir, interferon, foscarnet (non-nucleoside pyrophosphate analog), cytomegalovirus (CMV) hyperimmune globulin, and cytokines.
• •Patients with the following are excluded:
• •Immediately sight-threatening retinitis (= or \< 1500 microns from edge of optic disc, or inside major temporal vascular arcades, or = or \< 3000 microns from the fovea).
• •Ocular media opacities (corneal, lenticular, or vitreal) preventing ophthalmologic and photographic retinal assessment.
• •Demonstrated hypersensitivity to acyclovir.
• •Prior Medication:
• •Excluded:
• •\- Previous treatment with anti-cytomegalovirus therapy.